FDA
-
-
-
-
-
-
-
Ascendis reports sustained growth in achondroplasia trial subgroup
-
-
-
-
-
-
-
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Ascendis Pharma (ASND) as Yuviwel Approved for Achondroplasia
-
-
-
-
-
-
-
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Ascendis Pharma (ASND)
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on Ascendis Pharma (ASND)
-
-
-
-
-
-
-
Ascendis Pharma (ASND) Announces FDA Acceptance of TransCon CNP NDA for Priority Review
-
327,801 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

